Ventricular premature complexes (VPCs) are very common. Its prevalence varies with the different recording methods and population enrolled. The prognostic value of VPCs and non-sustained ventricular tachycardia (NSVT) relies on the underlying heart disease. Frequent VPCs may worsen heart failure and induce cardiomyopathy. NSVT is associated with a higher all-cause mortality and ventricular tachycardia inducibility in the patients with coronary artery disease and left ventricular dysfunction. Follow-up of this population should include assessment of left ventricular function. It has become evident to treat the frequent VPCs

especially in heart failure patients. Β-blockers are the first line medications to choose

while amiodarone can be used as needed in the presence of structural heart diseases and/or heart failure. Implantable cardioversion defibrillators are recommended for NSVT patients with ischemic heart disease and left ventricle dysfunction with induced sustained ventricular tachycardia. Catheter ablation is safe and effective for the drug-resistant symptomatic frequent VPCs. The benefits and risk associated with catheter ablation should be evaluated for the patients when it is considered as a first line therapy.